Exelan Pharmaceuticals Inc.

Exelan Pharmaceuticals Inc. Exelan Pharmaceuticals Division, a foreign-owned pharmaceutical manufacturer and distributor headquartered in Boca Raton, Florida, supplies generic and branded pharmaceutical products and bulk drug repackaging services to federal healthcare agencies as a prime contractor competing on an unrestricted, full-and-open basis. The company operates across 219 federal awards with a combined potential value of $3.68 billion, obligating $183.2 million year-to-date, and has experienced rapid growth—from eight awards in 2022 to fifty awards in 2026 alone.

Exelan's capability portfolio centers on pharmaceutical manufacturing, repackaging, and distribution. The company holds single-award Indefinite Delivery Contracts across a portfolio of critical medications: Tamsulosin Hydrochloride 0.4 mg capsules ($88.2 million ceiling), Diclofenac Sodium 1% topical gel ($63.1 million ceiling), Lisinopril tablets ($40.5 million ceiling), Nicotine 24-hour transdermal patches ($29.9 million ceiling), Finasteride tablets ($29.0 million ceiling), Prazosin HCL capsules ($28.8 million ceiling), Lisinopril combination tablets ($28.2 million ceiling), Escitalopram Oxalate tablets ($48.4 million ceiling), and Lenalidomide oncology and hematologic malignancy treatments. Beyond prescription drugs, Exelan performs bulk repackaging of over-the-counter products including ibuprofen tablets, with twenty-five delivery orders issued across a $15.6 million ibuprofen contract vehicle. Recent representative work includes a $74.1 million delivery order from the Office of the Assistant Secretary for Preparedness and Response for Oseltamivir Phosphate capsules (awarded June 28, 2025), a $3.3 million delivery order from Veterans Integrated Service Network 12 for Lenalidomide (awarded January 16, 2026), and a $16.3 million delivery order from Veterans Integrated Service Network 2 for Lenalidomide (awarded June 1, 2026).

Customer concentration is extreme: three customer entities account for 96% of combined potential value. Veterans Integrated Service Network 12 anchors the portfolio with fourteen awards worth $2.41 billion in combined potential value—nearly two-thirds of all dollars. The Department of Veterans Affairs National Acquisition Center, which operates the VA Pharmaceutical Prime Vendor Program, represents one hundred five awards worth $757.7 million and constitutes 48% of the award count. The Defense Logistics Agency Troop Support Medical placed sixteen awards worth $312.5 million. Within the VA network, other Veterans Integrated Service Networks place smaller but regular orders: VISN 21 (twenty-one awards, $3.6 million), VISN 15 (ten awards, $6.5 million), and VISN 22 (nine awards, $38.6 million). The concentration reflects Exelan's specialization in federal pharmaceutical supply; twenty-one distinct customer agencies were served, but VA components dominate.

Exelan's primary vehicle is the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), under which one hundred eighty-seven delivery orders carry $219.3 million in combined potential value. The company also holds numerous single-award IDIQs as the sole supplier: the Ramipril Capsules IDIQ with the National Acquisition Center ($12.8 million ceiling through March 2027), the Sildenafil Citrate Tablets IDIQ ($10.4 million ceiling through October 2026), the Oseltamivir Phosphate Capsules and Suspension IDIQ ($10.2 million ceiling through February 2027), the Cyclobenzaprine Tablets IDIQ ($7.7 million ceiling through June 2027), the Zonisamide Capsules IDIQ ($4.2 million ceiling through June 2027), and the Bumetanide Tablets IDIQ ($5.6 million ceiling through May 2027). A single-award Blanket Purchase Agreement with Veterans Integrated Service Network 22 for Lenalidomide carries a $21.2 million ceiling. All IDIQs and BPAs are structured as requirements contracts with base periods of one year and four successive one-year option periods; Exelan holds no multiple-award vehicles.

Activity trajectory shows accelerating volume: fourteen awards in 2024, thirty-nine in 2025, and fifty through October 2026. Thirty-two awards with ultimate completion dates within the next twenty-four months carry combined potential value of $141.9 million, creating significant recompete exposure across ibuprofen repackaging, several VA specialty pharmaceutical contracts, and multiple DLA supply vehicles. Exelan performs substantially all work at its primary Boca Raton facility and secondary locations in Cary, North Carolina; Summit, New Jersey; Ottawa, Ontario, Canada; and designated federal delivery points. The company operates exclusively as a prime contractor with no identified subcontractors, controlling the full supply chain for pharmaceutical manufacturing, repackaging, labeling, and distribution. Exelan maintains active System for Award Management registration and competes on an unrestricted basis across its entire federal footprint—no set-aside categories, no teaming arrangements, and no reliance on parent-company relationships define its posture. The vendor's foreign ownership does not restrict eligibility for federal pharmaceutical procurement; the company's value proposition rests on manufacturing scale, specialized repackaging capabilities, and uninterrupted supply commitment across critical medications serving veteran and military healthcare.